Immuron (IMRN) Cash & Current Investments (2016 - 2025)
Immuron (IMRN) posted quarterly Cash & Current Investments of $28.3 billion for Q3 2025, up 24281014.48% year-on-year from N/an in Q3 2024, and up 1415879.98% on a QoQ basis from $2.0 million in Q2 2025.
Immuron (IMRN) Cash & Current Investments (2016 - 2025) Analysis & Trends
Immuron (IMRN) has reported Cash & Current Investments for 10 consecutive years, with $28.3 billion the latest figure, recorded in Q3 2025.
- Quarterly Cash & Current Investments rose 24281014.48% year-over-year to $28.3 billion in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $28.3 billion (up 24281014.48% YoY) and the FY2025 annual result came in at $11.7 million, down 32.07% from the prior year.
- Cash & Current Investments advanced to $28.3 billion in Q3 2025 per IMRN's latest filing, from $2.0 million in the prior quarter.
- Over the last five years, Cash & Current Investments for IMRN reached as high as $28.3 billion in Q3 2025 and fell as low as $116573.2 in Q3 2024.
- A 5-year average of $2.0 billion and a median of $12.7 million in 2023 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2023 — Cash & Current Investments sank 98.9% — and 2025, when it jumped 24281014.48%.
- Year by year, Cash & Current Investments stood at $17.7 million in 2021, then retreated by 11.73% to $15.6 million in 2022, then declined by 14.67% to $13.3 million in 2023, then tumbled by 38.21% to $8.2 million in 2024, then soared by 343715.72% to $28.3 billion in 2025.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $28.3 billion, $2.0 million, and $8.2 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Immuron | 258.65 Mn | -28.05 Bn | - | 28.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 2, 2025 | 28.31 Bn |
| Jun 30, 2025 | 2.00 Mn |
| Dec 31, 2024 | 8.23 Mn |
| Sep 9, 2024 | 116,573.15 |
| Jun 30, 2024 | 8.23 Mn |
| Dec 31, 2023 | 13.32 Mn |
| Sep 28, 2023 | 12.12 Mn |
| Aug 30, 2023 | 171,597.64 |
| Jun 30, 2023 | 13.41 Mn |
| Dec 31, 2022 | 15.61 Mn |
| Aug 31, 2022 | 15.61 Mn |
| Jun 30, 2022 | 15.61 Mn |
| Dec 31, 2021 | 17.69 Mn |
| Jun 30, 2021 | 2.74 Mn |
| Dec 31, 2020 | 264,447.68 |
| Sep 1, 2020 | 5.12 Mn |
| Jun 30, 2020 | 2.30 Mn |
| Dec 31, 2019 | 5.12 Mn |
| Jun 30, 2019 | 5.12 Mn |
| Dec 31, 2018 | 4.73 Mn |